MAIA Biotechnology Inc. (MAIA AMEX) stock market data APIs
$1.1008
0.03(2.7%)
as of October 16, 2026
Try our APIs with
free plan!
MAIA Biotechnology Inc. Financial Data Overview
Price chart is built with
Anychart
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Prev. Close
1.1008
Open
1.1352
High
1.1599
Low
1.0888
52 wk Range
0.87-3.19
Market Cap
67 916 K
Shares Outstanding
61 742 K
EPS
-0.13
Beta
0.281
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with MAIA Biotechnology Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at €19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only €19.99
TRY NOW
Get MAIA Biotechnology Inc. data using free add-ons & libraries
Get MAIA Biotechnology Inc. Fundamental Data
MAIA Biotechnology Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
€
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-10
- EPS/Forecast: -0.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MAIA Biotechnology Inc. News
New
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-tr...
MAIA Activates Second U.S. Testing Site In Phase 2 THIO-101 For Ateganosine In Treating Lung Cancer
(RTTNews) - MAIA Biotechnology Inc. (MAIA), a clinical-stage biopharmaceutical company, on Wednesday, announced the expansion of the Phase 2 THIO-101 trial for Ateganosine in treating non-small cell l...
MAIA Advances Phase 3 THIO-104 Trial Of Ateganosine In NSCLC, Targets 100 Patients By Year-End
(RTTNews) - MAIA Biotechnology, Inc. (MAIA), a clinical-stage biopharmaceutical company, provided a patient enrolment update for its pivotal Phase 3 trial, THIO-104, evaluating its investigational tel...
MAIA Receives FDA Clearance To Expand Phase 2 THIO-101 Lung Cancer Trial In The U.S.
(RTTNews) - MAIA Biotechnology, Inc. (MAIA), a clinical-stage immuno-oncology company, announced that the U.S. Food and Drug Administration, or FDA, has cleared an amendment to MAIA's IND to commence ...
Get MAIA Biotechnology Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
€19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only €19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
€99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.